Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VSTM Stock Forecast 2026-2027
$5.08
Current Price
$446.40M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to VSTM Price Targets
+254.3%
To High Target of $18.00
+205.1%
To Median Target of $15.50
+57.5%
To Low Target of $8.00
VSTM Price Momentum
+12.9%
1 Week Change
+33.0%
1 Month Change
+5.6%
1 Year Change
-34.2%
Year-to-Date Change
-54.8%
From 52W High of $11.25
+48.1%
From 52W Low of $3.43
📊 TOP ANALYST CALLS
Did VSTM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Verastem is one of their latest high-conviction picks.
Latest VSTM Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, VSTM has a bullish consensus with a median price target of $15.50 (ranging from $8.00 to $18.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $5.08, the median forecast implies a 205.1% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jeet Mukherjee at BTIG, projecting a 254.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VSTM Analyst Ratings
9
Buy
0
Hold
0
Sell
VSTM Price Target Range
Low
$8.00
Average
$15.50
High
$18.00
Current: $5.08
Latest VSTM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VSTM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 2, 2026 | BTIG | Jeet Mukherjee | Buy | Maintains | $18.00 |
| Jun 24, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 24, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Jun 23, 2026 | Jefferies | Buy | Maintains | $N/A | |
| May 14, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| May 8, 2026 | BTIG | Buy | Maintains | $N/A | |
| Apr 23, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Apr 20, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Apr 10, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Apr 10, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 30, 2026 | Jefferies | Faisal Khurshid | Buy | Assumes | $15.00 |
| Mar 12, 2026 | BTIG | Jeet Mukherjee | Buy | Assumes | $19.00 |
| Feb 4, 2026 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Assumes | $18.00 |
| Oct 16, 2025 | Cantor Fitzgerald | Eric Schmidt | Overweight | Assumes | $N/A |
| Sep 9, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Aug 8, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Jun 25, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| May 9, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 10, 2025 | Jefferies | Buy | Initiates | $N/A | |
| Apr 9, 2025 | Mizuho | Outperform | Maintains | $N/A |
Verastem Inc. (VSTM) Competitors
The following stocks are similar to Verastem based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Verastem Inc. (VSTM) Financial Data
Verastem Inc. has a market capitalization of $446.40M with a P/E ratio of -1.7x. The company generates $49.59M in trailing twelve-month revenue with a 82.9% profit margin.
Revenue growth is +6.5% quarter-over-quarter, while maintaining an operating margin of -240.5% and return on equity of -786.2%.
Valuation Metrics
Market Cap
$446.40M
Enterprise Value
$299.23M
P/E Ratio
-1.7x
PEG Ratio
0.0x
Price/Sales
7.9x
Growth & Margins
Revenue Growth (YoY)
+6.5%
Gross Margin
+83.7%
Operating Margin
-240.5%
Net Margin
+82.9%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+40.7%
Current Ratio
3.0x
Debt/Equity
104.5x
ROE
-786.2%
ROA
-59.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Verastem Inc. (VSTM) Business Model
About Verastem Inc.
What They Do
Develops innovative cancer therapies.
Business Model
The company focuses on creating and commercializing targeted cancer treatments, particularly through small molecule inhibitors that disrupt cancer cell processes. It generates revenue by bringing these therapies to market and addressing unmet oncology needs.
Additional Information
Verastem Inc. is headquartered in Needham, Massachusetts, and is actively involved in advancing precision medicine. Its commitment to developing new treatment options positions it as a significant entity in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
102
CEO
Mr. Daniel W. Paterson
Country
United States
IPO Year
2012
Website
www.verastem.comVerastem Inc. (VSTM) Latest News & Analysis
Latest News
Quick Summary
Verastem Oncology granted 399,750 restricted stock units and stock options for 91,000 shares to new employees, under Nasdaq's inducement grant exception.
Why It Matters
Verastem's stock awards indicate confidence in future growth and talent acquisition, potentially enhancing company performance and affecting stock value positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Verastem, Inc. (VSTM) announced preliminary data from the TARGET-D 101 study on VS-7375, targeting KRAS G12D mutated cancers. Further details on efficacy and safety are anticipated.
Why It Matters
New data on VS-7375's efficacy in KRAS G12D cancers could influence Verastem's market position and stock performance, attracting investor interest in biotech innovation and potential growth.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
VS-7375, an investigational KRAS G12D ON/OFF inhibitor from $VSTM, shows clinical activity and a favorable safety profile in the TARGET-D 101 trial.
Why It Matters
Positive results for VS-7375 in the TARGET-D 101 trial could boost investor confidence in VSTM, potentially leading to increased stock value and interest in future drug developments.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Verastem, Inc. (NASDAQ: VSTM) shares rose following positive results from its RAMP 205 trial, which tests a drug combination for metastatic pancreatic cancer.
Why It Matters
Verastem's stock rise indicates positive investor sentiment following promising trial results, potentially boosting future revenue and market position in cancer treatment.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Verastem Oncology reported updated results from the RAMP 205 clinical trial for first-line metastatic pancreatic ductal adenocarcinoma.
Why It Matters
Verastem Oncology's trial results could impact its stock price and investor sentiment, especially in the competitive cancer treatment market. Positive outcomes may boost future sales potential.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Verastem, Inc. retains a Buy rating, with key data readouts from the TARGET-D 101 study expected in 2026 and promising early results for its cancer treatments.
Why It Matters
Verastem's Buy rating reflects confidence in its pipeline, especially with promising clinical data and key future study results, indicating potential stock value growth.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About VSTM Stock
What is Verastem Inc.'s (VSTM) stock forecast for 2027?
Based on our analysis of 15 Wall Street analysts, Verastem Inc. (VSTM) has a median price target of $15.50. The highest price target is $18.00 and the lowest is $8.00.
Is VSTM stock a good investment in 2027?
According to current analyst ratings, VSTM has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VSTM stock?
Wall Street analysts predict VSTM stock could reach $15.50 in the next 12 months. This represents a 205.1% increase from the current price of $5.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Verastem Inc.'s business model?
The company focuses on creating and commercializing targeted cancer treatments, particularly through small molecule inhibitors that disrupt cancer cell processes. It generates revenue by bringing these therapies to market and addressing unmet oncology needs.
What is the highest forecasted price for VSTM Verastem Inc.?
The highest price target for VSTM is $18.00 from Jeet Mukherjee at BTIG, which represents a 254.3% increase from the current price of $5.08.
What is the lowest forecasted price for VSTM Verastem Inc.?
The lowest price target for VSTM is $8.00 from at , which represents a 57.5% increase from the current price of $5.08.
What is the overall VSTM consensus from analysts for Verastem Inc.?
The overall analyst consensus for VSTM is bullish. Out of 15 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.50.
How accurate are VSTM stock price projections?
Stock price projections, including those for Verastem Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 4:09 AM UTC